Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alkermes has received a letter terminating the development and license agreement between Eli Lilly and Company and Alkermes dated April 1, 2001 that terminates the Air Inhaled Insulin program.
Subscribe to our email newsletter
The termination will become effective in 90 days. The termination of the agreement also results in the termination of the Air Insulin supply agreement. Alkermes is evaluating the impact of the termination of the Air Insulin program on its business and will provide further details following a comprehensive business analysis.